• Home
  • Search Results

Search Results

Open
Young Adult (18-34)
Cancer
178 studies match your search
Open

Phase 3 Study of RMC-6236 in Previously Treated NSCLC Patients with RAS Mutations

Have you been diagnosed with non-small cell lung cancer? Have you already been treated with an anti PDL-1 therapy and chemotherapy? If so, you may be able to take part in a research study looking to compare the safety and effectiveness of the investigational drug RMC-6236 to docetaxel.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
Open

Leukemia Treatment Study

Have you been diagnosed with Leukemia? Do you have a functioning kidney, liver, and cardiac organ? If so, you may be able to participate in a study on a new drug called Ziftomenib. We want to find out if it hooking their interest enough to click on the link to is safe for people with Leukemia. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Male, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Bladder Cancer Treatment Study

We're looking for people with bladder cancer to join a study on a new radiation treatment. If you have bladder cancer, this study will tests if receiving higher doses of radiation in a shorter time, along with chemotherapy, works as well as standard treatments. Participating may help you avoid surgery to remove your bladder. It may also mean you finish treatment faster, which might fit better with your needs. Overall, by joining the study you can contribute to improving future bladder cancer care for you and others.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder)
  • Urinary and Bladder
Open

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

Are you 18 years or older and diagnosed with HER2+, clinical stage T1c-T3 (or Tx) and nodal stage N0-N1 breast cancer and prior to surgery did you received chemotherapy in combination with Trastuzumab for a minimum of 12 weeks? If so, you may be eligible for a research study evaluating the effectiveness of 6 months of HER2-targeted medications (trastuzumab with or without pertuzumab) versus 12 months of HER2-targeted medications at reducing the risk of breast cancer coming back or death in patients.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Do you have Stage III or IV Squamous Cell Skin Cancer that is considered high risk? If so,you may be able to take part in a research study evaluating combination therapies versus the standard approach for your type of cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Open

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Are you a patient with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)? If so this could be the study for you. The purpose of this study is to investigate if the sonrotoclax in combination with obinutuzumab or rituximab works better and is safe in participants with

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
Open

Treatment with PUL-042 in Patients with Parainfluenza, Human Metapneumovirus, or Respiratory Syncytial Virus

Do you have a blood cancer or have received a stem cell transplant and have been diagnosed with a respiratory infection? If so, you might be eligible to take part in a study to see if an experimental treatment is effective at reducing the severity of the respiratory infection.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Other Cancers, Leukemia, Lymphoma, Multiple Myeloma)
  • Transplant
Open

Study for a new treatment for a type of blood cancer, Acute Myeloid Leukemia (AML)

Do you have Acute Myeloid Leukemia (AML) and want to try a new study drug that might help treat your cancer?

Age & Gender
  • 18 years ~ 60 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Zilovertamab Vedotin+R-CHP vs Polatuzumab Vedotin+R-CHP for 1L DLBCL, GCB

Have you been diagnosed with GCB Subtype of Diffuse LargeB-cell Lymphoma (DLBCL)? If so, you may be able to take part in a research study looking at Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Open

Evaluating Combinations of Medications After Stem Cell Transplant to Prevent Graft versus Host Disease and Infections

Do you have leukemia, lymphoma, MDS, or MF and are preparing for a stem cell transplant from an unrelated donor? If so, you might be eligible to take part in a study that will look look at combinations of medicines given after a stem cell transplant and see how well the combinations work to prevent graft versus host disease and infection.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Other Cancers, Leukemia, Lymphoma)
  • Transplant
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research